Sussex Partnership NHS Foundation Trust, UK.
University of Coimbra, Faculty of Psychology and Educational Sciences, Portugal.
Schizophr Res. 2023 Nov;261:269-274. doi: 10.1016/j.schres.2023.10.004. Epub 2023 Oct 18.
Whilst antipsychotic medication reduces risk of relapse following a first episode of psychosis (FEP), some individuals can discontinue medication and remain relapse free. We aimed to identify patient and service-specific factors which influence clinical outcome following antipsychotic discontinuation. The outcomes 'admission to hospital' and 'remaining free from psychotic symptoms', both within one year from discontinuation, were explored retrospectively in an established naturalistic cohort of 354 patients with FEP. Logistic regression analysis was used to explore influence of routinely available baseline and treatment course variables on these outcomes. Seventy-seven individuals (22 %) fully discontinued antipsychotic treatment within a year, at mean 102 days from initiation. Only antipsychotic type had significant association with discontinuation; aripiprazole was discontinued more than olanzapine (p = 0.028). Seventeen individuals required admission to hospital; significantly associated with prior admission at first illness onset (p = 0.004), and prior legal detention to hospital (p = 0.001). Admission was less likely in those discontinuing aripiprazole vs olanzapine (p = 0.044). Twenty-four patients remained psychosis symptom free and were most significantly likely to have received clinician support in discontinuation; this group had no association with either initial duration of untreated psychosis or prior duration of antipsychotic treatment. Future studies exploring outcomes following antipsychotic discontinuation require consistency of choice of outcome measures and sample stratification by vulnerability factors including severity of first illness episode, whether remaining symptom free after first episode, which medication switched from and baseline functioning. The impact and nature of clinician support to discontinue requires further exploration alongside its association with abruptness of discontinuation.
虽然抗精神病药物可降低首发精神病 (FEP) 后复发的风险,但有些患者可以停药且不复发。我们旨在确定影响抗精神病药停药后临床结局的患者和服务特定因素。回顾性分析了一个既定的自然队列 354 名 FEP 患者,在停药后一年内评估“住院”和“无精神病症状”这两个结局。使用逻辑回归分析来探索常规基线和治疗过程变量对这些结局的影响。77 名患者(22%)在一年内完全停止抗精神病药物治疗,平均停药时间为开始治疗后 102 天。只有抗精神病药物类型与停药有显著关联;阿立哌唑的停药率高于奥氮平(p=0.028)。17 名患者需要住院治疗;与首次发病时的既往住院(p=0.004)和既往因法律原因住院(p=0.001)显著相关。与奥氮平相比,阿立哌唑停药的患者住院的可能性较小(p=0.044)。24 名患者保持无精神病症状,最有可能在停药时得到临床医生的支持;该组与未治疗精神病的初始持续时间或之前的抗精神病药物治疗持续时间均无关联。未来探索抗精神病药停药后结局的研究需要一致性地选择结局测量方法,并按易感性因素分层,包括首发疾病的严重程度、首次发病后是否仍无症状、从哪种药物转换以及基线功能。还需要进一步探索临床医生支持停药的影响和性质,以及其与停药突然性的关联。